Silverfin false 31/03/2023 01/02/2022 31/03/2023 Dr S C Hasting 01/05/2022 Dr K Pirie 30/04/2023 01/02/2022 Dr J A Taylor 01/02/2022 Mrs L C Taylor 01/05/2022 31 October 2023 SO307490 2023-03-31 SO307490 bus:Director1 2023-03-31 SO307490 bus:Director2 2023-03-31 SO307490 bus:Director3 2023-03-31 SO307490 bus:Director4 2023-03-31 SO307490 core:CurrentFinancialInstruments 2023-03-31 SO307490 core:Non-currentFinancialInstruments 2023-03-31 SO307490 core:OtherPropertyPlantEquipment 2022-01-31 SO307490 2022-01-31 SO307490 core:OtherPropertyPlantEquipment 2023-03-31 SO307490 2022-02-01 2023-03-31 SO307490 bus:FullAccounts 2022-02-01 2023-03-31 SO307490 bus:SmallEntities 2022-02-01 2023-03-31 SO307490 bus:AuditExemptWithAccountantsReport 2022-02-01 2023-03-31 SO307490 bus:LimitedLiabilityPartnershipLLP 2022-02-01 2023-03-31 SO307490 bus:Director1 2022-02-01 2023-03-31 SO307490 bus:Director2 2022-02-01 2023-03-31 SO307490 bus:Director3 2022-02-01 2023-03-31 SO307490 bus:Director4 2022-02-01 2023-03-31 SO307490 core:OtherPropertyPlantEquipment 2022-02-01 2023-03-31 iso4217:GBP xbrli:pure

Company No: SO307490 (Scotland)

AUCHENBLAE MEDICAL PRACTICE LLP

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL PERIOD FROM 01 FEBRUARY 2022 TO 31 MARCH 2023
PAGES FOR FILING WITH THE REGISTRAR

AUCHENBLAE MEDICAL PRACTICE LLP

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL PERIOD FROM 01 FEBRUARY 2022 TO 31 MARCH 2023

Contents

AUCHENBLAE MEDICAL PRACTICE LLP

BALANCE SHEET

AS AT 31 MARCH 2023
AUCHENBLAE MEDICAL PRACTICE LLP

BALANCE SHEET (continued)

AS AT 31 MARCH 2023
Note 31.03.2023
£
Fixed assets
Tangible assets 3 2,190
2,190
Current assets
Stocks 28,456
Debtors
- due within one year 4 63,173
- due after more than one year 4 62,176
Cash at bank and in hand ( 549)
153,256
Creditors: amounts falling due within one year 5 ( 75,914)
Net current assets 77,342
Total assets less current liabilities 79,532
Net assets attributable to members 79,532
Represented by
Loans and other debts due to members within one year
Members' capital classified as a liability 34,615
Other amounts 44,917
79,532
Members' other interests
0
79,532
Total members' interests
Loans and other debts due to members 79,532
79,532

For the financial period ending 31 March 2023 the LLP was entitled to exemption from audit under section 477 of the Companies Act 2006, as applied by The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008.

Members' responsibilities:

Auchenblae Medical Practice LLP has no equity and, in accordance with the provisions contained within the Statement of Recommended Practice "Accounting by Limited Liability Partnerships", has not presented a Statement of Changes in Equity.

The financial statements of Auchenblae Medical Practice LLP (registered number: SO307490) were approved and authorised for issue by the Director on 31 October 2023. They were signed on its behalf by:

Dr J A Taylor
Designated member
AUCHENBLAE MEDICAL PRACTICE LLP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL PERIOD FROM 01 FEBRUARY 2022 TO 31 MARCH 2023
AUCHENBLAE MEDICAL PRACTICE LLP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL PERIOD FROM 01 FEBRUARY 2022 TO 31 MARCH 2023
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.

General information and basis of accounting

Auchenblae Medical Practice LLP is a limited liability partnership, incorporated in the United Kingdom under the Limited Liability Partnerships Act 2000 and is registered in Scotland. The address of the LLP's registered office is Mackenzie Avenue, Auchenblae, Laurencekirk, AB30 1XU, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Limited Liability Partnerships Act 2000 as applicable to companies subject to the small companies regime and the requirements of the Statement of Recommended Practice Accounting by Limited Liability Partnerships issued in December 2021 (SORP 2022).

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The members have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The members have a reasonable expectation that the LLP has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover represents amounts earned during the year from medical activities.

If, at the balance sheet date, completion of contractual obligations is dependent on external factors (and thus outside the control of the Limited Liability Partnership), then revenue is recognised only when the event occurs. In such cases, costs incurred up to the balance sheet date are carried forward as work in progress.

Taxation

The taxation payable on the partnership's profits is the personal liability of the members, although payment of such liabilities is administered by the partnership on behalf of its members. Consequently, neither partnership taxation nor related deferred taxation is accounted for in these financial statements. Sums set aside in respect of members' tax obligations are included in the balance sheet within loans and other debts due to members, or are set against amounts due from members as appropriate.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. 15 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Stocks

The stock of drugs is valued at the lower of cost or net realisable value.

2. Employees

Period from
01.02.2022 to
31.03.2023
Number
Monthly average number of persons employed by the LLP during the period 10

3. Tangible assets

Plant and machinery etc. Total
£ £
Cost
At 01 February 2022 0 0
Additions 2,539 2,539
At 31 March 2023 2,539 2,539
Accumulated depreciation
At 01 February 2022 0 0
Charge for the financial period 349 349
At 31 March 2023 349 349
Net book value
At 31 March 2023 2,190 2,190

4. Debtors

31.03.2023
£
Debtors: amounts falling due within one year
Other debtors 63,173
Debtors: amounts falling due after more than one year
Other debtors 62,176

5. Creditors: amounts falling due within one year

31.03.2023
£
Trade creditors 55,050
Other creditors 20,864
75,914